. 2017 Oct;44(10):1529-1535.

doi: 10.3899/jrheum.161139. Epub 2017 Sep 1.

OMERACT Endorsement of Patient-reported Outcome Instruments in Antineutrophil Cytoplasmic Antibody-associated Vasculitis

Joanna C Robson^{1

2}, Gunnar Tomasson^{1

2}, Nataliya Milman^{1

2}, Sue Ashdown^{1

2}, Annelies Boonen^{1

2}, George C Casey^{1

2}, Peter F Cronholm^{1

2}, David Cuthbertson^{1

2}, Jill Dawson^{1

2}, Haner Direskeneli^{1

2}, Ebony Easley^{1

2}, Tanaz A Kermani^{1

2}, John T Farrar^{1

2}, Don Gebhart^{1

2}, Georgia Lanier^{1

2}, Raashid A Luqmani^{1

2}, Alfred Mahr^{1

2}, Carol A McAlear^{1

2}, Jacqueline Peck^{1

2}, Beverley Shea^{1

2}, Judy A Shea^{1

2}, Antoine G Sreih^{1

2}, Peter S Tugwell^{1

2}, Peter A Merkel^{3

4}

Affiliations

¹ From the University of the West of England; University of Bristol; University Hospitals Bristol UK National Health Service (NHS) Trust, Bristol; Nuffield Department of Population Health, University of Oxford; Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; Department of Public Health Sciences, University of Iceland, Reykjavik, Iceland; Division of Rheumatology, University of Ottawa; Division of Rheumatology, The Ottawa Hospital; Department of Clinical Epidemiology, Ottawa Hospital Research Institute; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; Department of Medicine, Faculty of Medicine, University of Ottawa; Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa, Ontario, Canada; Division of Rheumatology, Maastricht University Medical Centre; Caphri Graduate School, Maastricht, the Netherlands; Vasculitis Foundation, Denver, Colorado; Department of Family Medicine and Community Health, University of Pennsylvania; Epidemiology, Neurology, and Anesthesiology, Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania; Department of Medicine, University of Pennsylvania; Clinical Medicine, Division of Rheumatology, University of Pennsylvania; Medicine and Epidemiology, Division of Rheumatology, Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania; Division of Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, Florida; Division of Rheumatology, Department of Medicine, University of California, Los Angeles, USA; Division of Rheumatology, Marmara University, School of Medicine, Marmara, Turkey; Medicine, Hopital Saint Louis, Paris, France.
² J.C. Robson, MRCP, PhD, Consultant Senior Lecturer, University of the West of England, and Honorary Senior Lecturer, University of Bristol, and Honorary Consultant in Rheumatology, University Hospitals Bristol UK NHS Trust; G. Tomasson, MD, PhD, Assistant Professor of Medicine, Department of Public Health Sciences, University of Iceland; N. Milman, MD, Assistant Professor, Division of Rheumatology, University of Ottawa, and Division of Rheumatology, The Ottawa Hospital, and Department of Clinical Epidemiology, Ottawa Hospital Research Institute; S. Ashdown, RGN, RM, Patient-Partner; A. Boonen, MD, PhD, Professor of Rheumatology, Division of Rheumatology, Maastricht University Medical Centre, and Caphri Graduate School; George C. Casey, MBA, Patient-Partner, Vasculitis Foundation; P.F. Cronholm, MD, MSCE, Associate Professor of Family Medicine, Department of Family Medicine and Community Health, University of Pennsylvania; D. Cuthbertson, MA, Division of Biostatistics and Informatics, Department of Pediatrics, University of South Florida; J. Dawson, MA, MSc, DPhil, SRN, SCM, Associate Professor, Nuffield Department of Population Health, University of Oxford; H. Direskeneli, MD, Professor of Medicine, Division of Rheumatology, Marmara University, School of Medicine; E. Easley, Department of Family Medicine and Community Health, University of Pennsylvania; T.A. Kermani, MD, MS, Assistant Professor of Medicine, Division of Rheumatology, Department of Medicine, University of California; J.T. Farrar, MD, PhD, Associate Professor of Epidemiology, Neurology, and Anesthesiology, Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania; D. Gebhart, MD, Patient-Partner; G. Lanier, Patient-Partner; R.A. Luqmani, DM, FRCP, FRCP(E), Professor of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford; A. Mahr, MD, PhD, Professor of Medicine, Hopital Saint Louis; C.A. McAlear, MA, Division of Rheumatology, University of Pennsylvania; J. Peck, RN, Patient-Partner; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; J.A. Shea, PhD, Professor of Medicine, Department of Medicine, University of Pennsylvania; A.G. Sreih, MD, Assistant Professor of Clinical Medicine, Division of Rheumatology, University of Pennsylvania; P.S. Tugwell, MD, MSc, Professor, Department of Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program, and School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; P.A. Merkel, MD, MPH, Professor of Medicine and Epidemiology, Division of Rheumatology, Department of Biostatistics, Epidemiology, and Informatics, and Department of Medicine, University of Pennsylvania.
³ From the University of the West of England; University of Bristol; University Hospitals Bristol UK National Health Service (NHS) Trust, Bristol; Nuffield Department of Population Health, University of Oxford; Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; Department of Public Health Sciences, University of Iceland, Reykjavik, Iceland; Division of Rheumatology, University of Ottawa; Division of Rheumatology, The Ottawa Hospital; Department of Clinical Epidemiology, Ottawa Hospital Research Institute; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; Department of Medicine, Faculty of Medicine, University of Ottawa; Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa, Ontario, Canada; Division of Rheumatology, Maastricht University Medical Centre; Caphri Graduate School, Maastricht, the Netherlands; Vasculitis Foundation, Denver, Colorado; Department of Family Medicine and Community Health, University of Pennsylvania; Epidemiology, Neurology, and Anesthesiology, Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania; Department of Medicine, University of Pennsylvania; Clinical Medicine, Division of Rheumatology, University of Pennsylvania; Medicine and Epidemiology, Division of Rheumatology, Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania; Division of Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, Florida; Division of Rheumatology, Department of Medicine, University of California, Los Angeles, USA; Division of Rheumatology, Marmara University, School of Medicine, Marmara, Turkey; Medicine, Hopital Saint Louis, Paris, France. pmerkel@upenn.edu.
⁴ J.C. Robson, MRCP, PhD, Consultant Senior Lecturer, University of the West of England, and Honorary Senior Lecturer, University of Bristol, and Honorary Consultant in Rheumatology, University Hospitals Bristol UK NHS Trust; G. Tomasson, MD, PhD, Assistant Professor of Medicine, Department of Public Health Sciences, University of Iceland; N. Milman, MD, Assistant Professor, Division of Rheumatology, University of Ottawa, and Division of Rheumatology, The Ottawa Hospital, and Department of Clinical Epidemiology, Ottawa Hospital Research Institute; S. Ashdown, RGN, RM, Patient-Partner; A. Boonen, MD, PhD, Professor of Rheumatology, Division of Rheumatology, Maastricht University Medical Centre, and Caphri Graduate School; George C. Casey, MBA, Patient-Partner, Vasculitis Foundation; P.F. Cronholm, MD, MSCE, Associate Professor of Family Medicine, Department of Family Medicine and Community Health, University of Pennsylvania; D. Cuthbertson, MA, Division of Biostatistics and Informatics, Department of Pediatrics, University of South Florida; J. Dawson, MA, MSc, DPhil, SRN, SCM, Associate Professor, Nuffield Department of Population Health, University of Oxford; H. Direskeneli, MD, Professor of Medicine, Division of Rheumatology, Marmara University, School of Medicine; E. Easley, Department of Family Medicine and Community Health, University of Pennsylvania; T.A. Kermani, MD, MS, Assistant Professor of Medicine, Division of Rheumatology, Department of Medicine, University of California; J.T. Farrar, MD, PhD, Associate Professor of Epidemiology, Neurology, and Anesthesiology, Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania; D. Gebhart, MD, Patient-Partner; G. Lanier, Patient-Partner; R.A. Luqmani, DM, FRCP, FRCP(E), Professor of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford; A. Mahr, MD, PhD, Professor of Medicine, Hopital Saint Louis; C.A. McAlear, MA, Division of Rheumatology, University of Pennsylvania; J. Peck, RN, Patient-Partner; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; J.A. Shea, PhD, Professor of Medicine, Department of Medicine, University of Pennsylvania; A.G. Sreih, MD, Assistant Professor of Clinical Medicine, Division of Rheumatology, University of Pennsylvania; P.S. Tugwell, MD, MSc, Professor, Department of Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program, and School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; P.A. Merkel, MD, MPH, Professor of Medicine and Epidemiology, Division of Rheumatology, Department of Biostatistics, Epidemiology, and Informatics, and Department of Medicine, University of Pennsylvania. pmerkel@upenn.edu.

PMID: 28864650
PMCID: PMC5951181
DOI: 10.3899/jrheum.161139

OMERACT Endorsement of Patient-reported Outcome Instruments in Antineutrophil Cytoplasmic Antibody-associated Vasculitis

Joanna C Robson et al. J Rheumatol. 2017 Oct.

. 2017 Oct;44(10):1529-1535.

doi: 10.3899/jrheum.161139. Epub 2017 Sep 1.

Authors

Affiliations

¹ From the University of the West of England; University of Bristol; University Hospitals Bristol UK National Health Service (NHS) Trust, Bristol; Nuffield Department of Population Health, University of Oxford; Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; Department of Public Health Sciences, University of Iceland, Reykjavik, Iceland; Division of Rheumatology, University of Ottawa; Division of Rheumatology, The Ottawa Hospital; Department of Clinical Epidemiology, Ottawa Hospital Research Institute; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; Department of Medicine, Faculty of Medicine, University of Ottawa; Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa, Ontario, Canada; Division of Rheumatology, Maastricht University Medical Centre; Caphri Graduate School, Maastricht, the Netherlands; Vasculitis Foundation, Denver, Colorado; Department of Family Medicine and Community Health, University of Pennsylvania; Epidemiology, Neurology, and Anesthesiology, Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania; Department of Medicine, University of Pennsylvania; Clinical Medicine, Division of Rheumatology, University of Pennsylvania; Medicine and Epidemiology, Division of Rheumatology, Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania; Division of Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, Florida; Division of Rheumatology, Department of Medicine, University of California, Los Angeles, USA; Division of Rheumatology, Marmara University, School of Medicine, Marmara, Turkey; Medicine, Hopital Saint Louis, Paris, France.
² J.C. Robson, MRCP, PhD, Consultant Senior Lecturer, University of the West of England, and Honorary Senior Lecturer, University of Bristol, and Honorary Consultant in Rheumatology, University Hospitals Bristol UK NHS Trust; G. Tomasson, MD, PhD, Assistant Professor of Medicine, Department of Public Health Sciences, University of Iceland; N. Milman, MD, Assistant Professor, Division of Rheumatology, University of Ottawa, and Division of Rheumatology, The Ottawa Hospital, and Department of Clinical Epidemiology, Ottawa Hospital Research Institute; S. Ashdown, RGN, RM, Patient-Partner; A. Boonen, MD, PhD, Professor of Rheumatology, Division of Rheumatology, Maastricht University Medical Centre, and Caphri Graduate School; George C. Casey, MBA, Patient-Partner, Vasculitis Foundation; P.F. Cronholm, MD, MSCE, Associate Professor of Family Medicine, Department of Family Medicine and Community Health, University of Pennsylvania; D. Cuthbertson, MA, Division of Biostatistics and Informatics, Department of Pediatrics, University of South Florida; J. Dawson, MA, MSc, DPhil, SRN, SCM, Associate Professor, Nuffield Department of Population Health, University of Oxford; H. Direskeneli, MD, Professor of Medicine, Division of Rheumatology, Marmara University, School of Medicine; E. Easley, Department of Family Medicine and Community Health, University of Pennsylvania; T.A. Kermani, MD, MS, Assistant Professor of Medicine, Division of Rheumatology, Department of Medicine, University of California; J.T. Farrar, MD, PhD, Associate Professor of Epidemiology, Neurology, and Anesthesiology, Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania; D. Gebhart, MD, Patient-Partner; G. Lanier, Patient-Partner; R.A. Luqmani, DM, FRCP, FRCP(E), Professor of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford; A. Mahr, MD, PhD, Professor of Medicine, Hopital Saint Louis; C.A. McAlear, MA, Division of Rheumatology, University of Pennsylvania; J. Peck, RN, Patient-Partner; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; J.A. Shea, PhD, Professor of Medicine, Department of Medicine, University of Pennsylvania; A.G. Sreih, MD, Assistant Professor of Clinical Medicine, Division of Rheumatology, University of Pennsylvania; P.S. Tugwell, MD, MSc, Professor, Department of Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program, and School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; P.A. Merkel, MD, MPH, Professor of Medicine and Epidemiology, Division of Rheumatology, Department of Biostatistics, Epidemiology, and Informatics, and Department of Medicine, University of Pennsylvania.
³ From the University of the West of England; University of Bristol; University Hospitals Bristol UK National Health Service (NHS) Trust, Bristol; Nuffield Department of Population Health, University of Oxford; Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; Department of Public Health Sciences, University of Iceland, Reykjavik, Iceland; Division of Rheumatology, University of Ottawa; Division of Rheumatology, The Ottawa Hospital; Department of Clinical Epidemiology, Ottawa Hospital Research Institute; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; Department of Medicine, Faculty of Medicine, University of Ottawa; Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa, Ontario, Canada; Division of Rheumatology, Maastricht University Medical Centre; Caphri Graduate School, Maastricht, the Netherlands; Vasculitis Foundation, Denver, Colorado; Department of Family Medicine and Community Health, University of Pennsylvania; Epidemiology, Neurology, and Anesthesiology, Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania; Department of Medicine, University of Pennsylvania; Clinical Medicine, Division of Rheumatology, University of Pennsylvania; Medicine and Epidemiology, Division of Rheumatology, Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania; Division of Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, Florida; Division of Rheumatology, Department of Medicine, University of California, Los Angeles, USA; Division of Rheumatology, Marmara University, School of Medicine, Marmara, Turkey; Medicine, Hopital Saint Louis, Paris, France. pmerkel@upenn.edu.
⁴ J.C. Robson, MRCP, PhD, Consultant Senior Lecturer, University of the West of England, and Honorary Senior Lecturer, University of Bristol, and Honorary Consultant in Rheumatology, University Hospitals Bristol UK NHS Trust; G. Tomasson, MD, PhD, Assistant Professor of Medicine, Department of Public Health Sciences, University of Iceland; N. Milman, MD, Assistant Professor, Division of Rheumatology, University of Ottawa, and Division of Rheumatology, The Ottawa Hospital, and Department of Clinical Epidemiology, Ottawa Hospital Research Institute; S. Ashdown, RGN, RM, Patient-Partner; A. Boonen, MD, PhD, Professor of Rheumatology, Division of Rheumatology, Maastricht University Medical Centre, and Caphri Graduate School; George C. Casey, MBA, Patient-Partner, Vasculitis Foundation; P.F. Cronholm, MD, MSCE, Associate Professor of Family Medicine, Department of Family Medicine and Community Health, University of Pennsylvania; D. Cuthbertson, MA, Division of Biostatistics and Informatics, Department of Pediatrics, University of South Florida; J. Dawson, MA, MSc, DPhil, SRN, SCM, Associate Professor, Nuffield Department of Population Health, University of Oxford; H. Direskeneli, MD, Professor of Medicine, Division of Rheumatology, Marmara University, School of Medicine; E. Easley, Department of Family Medicine and Community Health, University of Pennsylvania; T.A. Kermani, MD, MS, Assistant Professor of Medicine, Division of Rheumatology, Department of Medicine, University of California; J.T. Farrar, MD, PhD, Associate Professor of Epidemiology, Neurology, and Anesthesiology, Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania; D. Gebhart, MD, Patient-Partner; G. Lanier, Patient-Partner; R.A. Luqmani, DM, FRCP, FRCP(E), Professor of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford; A. Mahr, MD, PhD, Professor of Medicine, Hopital Saint Louis; C.A. McAlear, MA, Division of Rheumatology, University of Pennsylvania; J. Peck, RN, Patient-Partner; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; J.A. Shea, PhD, Professor of Medicine, Department of Medicine, University of Pennsylvania; A.G. Sreih, MD, Assistant Professor of Clinical Medicine, Division of Rheumatology, University of Pennsylvania; P.S. Tugwell, MD, MSc, Professor, Department of Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program, and School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; P.A. Merkel, MD, MPH, Professor of Medicine and Epidemiology, Division of Rheumatology, Department of Biostatistics, Epidemiology, and Informatics, and Department of Medicine, University of Pennsylvania. pmerkel@upenn.edu.

PMID: 28864650
PMCID: PMC5951181
DOI: 10.3899/jrheum.161139

Abstract

Objective: The antineutrophil cytoplasmic antibody-associated vasculitides (AAV) are multiorgan diseases. Patients with AAV report impairment in their health-related quality of life (HRQOL) and have different priorities regarding disease assessment compared with physicians. The Outcome Measures in Rheumatology (OMERACT) Vasculitis Working Group previously received endorsement for a core set of domains in AAV. Two approaches to measure patient-reported outcomes (PRO) were presented at OMERACT 2016.

Methods: A novel 5-step tool was used to facilitate assessment of the instruments by delegates: the OMERACT Filter 2.0 Instrument Selection Algorithm, with a red-amber-green checklist of questions, including (1) good match with domain (face and content validity), (2) feasibility, (3) do numeric scores make sense (construct validity)?, (4) overall ratings of discrimination, and (5) can individual thresholds of meaning be defined? Delegates gave an overall endorsement. Three generic Patient-Reported Outcomes Measurement Information System (PROMIS) instruments (fatigue, physical functioning, and pain interference) and a disease-specific PRO, the AAV-PRO (6 domains related to symptoms and HRQOL), were presented.

Results: OMERACT delegates endorsed the use of the PROMIS instruments for fatigue, physical functioning, and pain interference (87.6% overall endorsement) and the disease-specific AAV-PRO instrument (89.4% overall endorsement).

Conclusion: The OMERACT Vasculitis Working Group gained endorsement by OMERACT for use of the PROMIS and the AAV-PRO in clinical trials of vasculitis. These instruments are complementary to each other. The PROMIS and the AAV-PRO need further work to assess their utility in longitudinal settings, including their ability to discriminate between treatments of varying efficacy in the setting of a randomized controlled trial.

Keywords: ANCA-ASSOCIATED VASCULITIS; ICF; OMERACT; PATIENT-REPORTED OUTCOMES; PROMIS.

PubMed Disclaimer

Figures

**Figure 1**
The OMERACT Filter 2.0 Instrument Selection Algorithm (OFISA) and red-amber-green checklist. Adapted with permission from the OMERACT Handbook. OMERACT: Outcome Measures in Rheumatology; R: red; A: amber; G: green.

**Figure 2**
Full evaluation of Core Outcome Measurement Sets is to be completed (5.D.1–12; The OMERACT Handbook: www.omeract.org/pdf/OMERACT_Handbook.pdf). OMERACT master checklist for developing Core Outcome Measurement Sets. OMERACT: Outcome Measures in Rheumatology; ANCA: antineutrophil cytoplasmic antibody; PROMIS: Patient-Reported Outcomes Measurement Information System; OFISA: OMERACT Filter 2.0 Instrument Selection Algorithm; RCT: randomized controlled trial; AAV-PRO: patient-reported outcome measure for ANCA–associated vasculitis.

**Figure 3**
OMERACT endorsement of PRO in AAV. (A) PROMIS instruments for fatigue, physical functioning, and pain interference for AAV voting results. (B) The disease-specific AAV-PRO voting results. OMERACT endorsement set at ≥ 70% of votes (sum of Green or Amber). Green (OK): Yes, I agree; Amber (OK): I am okay with this, but have some reservations, more work needed in this area; Red (Not OK): I disagree; Grey: Insufficient evidence or information. OMERACT: Outcome Measures in Rheumatology; PRO: patient-reported outcomes; ANCA: antineutrophil cytoplasmic antibody; AAV: ANCA–associated vasculitis; PROMIS: Patient-Reported Outcomes Measurement Information System; AAV-PRO: PRO measure for AAV.

See this image and copyright information in PMC

Cited by

Retinal thickness and microvascular alterations observed by optical coherence tomography in antineutrophil cytoplasmic antibody-associated vasculitis: a cross-sectional study.
Li ZY, Kang M, Qian XZ, Peng R, Hong Q, Ying P, Huang H, Wang XY, Zeng YM, Hu JY, Chen X, Wu R, Shao Y, Yu SJ. Li ZY, et al. Quant Imaging Med Surg. 2024 Jul 1;14(7):4998-5011. doi: 10.21037/qims-23-1717. Epub 2024 Jun 27. Quant Imaging Med Surg. 2024. PMID: 39022287 Free PMC article.
ANCA-associated vasculitis.
Kitching AR, Anders HJ, Basu N, Brouwer E, Gordon J, Jayne DR, Kullman J, Lyons PA, Merkel PA, Savage COS, Specks U, Kain R. Kitching AR, et al. Nat Rev Dis Primers. 2020 Aug 27;6(1):71. doi: 10.1038/s41572-020-0204-y. Nat Rev Dis Primers. 2020. PMID: 32855422 Review.
[Management of ANCA-associated vasculitides].
Löffler C, Hellmich B. Löffler C, et al. Inn Med (Heidelb). 2024 Feb;65(2):93-106. doi: 10.1007/s00108-023-01655-2. Epub 2024 Jan 22. Inn Med (Heidelb). 2024. PMID: 38253699 Review. German.
Treatment goals in ANCA-associated vasculitis: defining success in a new era.
Alberici F, Tedesco M, Popov T, Balcells-Oliver M, Mescia F. Alberici F, et al. Front Immunol. 2024 Jun 13;15:1409129. doi: 10.3389/fimmu.2024.1409129. eCollection 2024. Front Immunol. 2024. PMID: 38938575 Free PMC article. Review.
Systemic vasculitis and patient-reported outcomes: how the assessment of patient preferences and perspectives could improve outcomes.
Robson JC, Jayne D, Merkel PA, Dawson J. Robson JC, et al. Patient Relat Outcome Meas. 2019 Feb 8;10:37-42. doi: 10.2147/PROM.S163601. eCollection 2019. Patient Relat Outcome Meas. 2019. PMID: 30804691 Free PMC article. Review.

See all "Cited by" articles

References

1. Alberici F, Smith RM, Jones RB, Roberts DM, Willcocks LC, Chaudhry A, et al. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Rheumatology. 2015;54:1153–60. - PMC - PubMed
1. Little MA, Nightingale P, Verburgh CA, Hauser T, De Groot K, Savage C, et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis. 2010;69:1036–43. - PubMed
1. Robson J, Doll H, Suppiah R, Flossmann O, Harper L, Höglund P, et al. Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials. Ann Rheum Dis. 2015;74:177–84. - PubMed
1. Seo P, Min YI, Holbrook JT, Hoffman GS, Merkel PA, Spiera R, et al. WGET Research Group. Damage caused by Wegener’s granulomatosis and its treatment: prospective data from the Wegener’s Granulomatosis Etanercept Trial (WGET) Arthritis Rheum. 2005;52:2168–78. - PubMed
1. Walsh M, Mukhtyar C, Mahr A, Herlyn K, Luqmani R, Merkel PA, et al. Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2011;63:1055–61. - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

OMERACT Endorsement of Patient-reported Outcome Instruments in Antineutrophil Cytoplasmic Antibody-associated Vasculitis

Affiliations

OMERACT Endorsement of Patient-reported Outcome Instruments in Antineutrophil Cytoplasmic Antibody-associated Vasculitis

Authors

Affiliations

Abstract

Figures

Similar articles

Cited by

References

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Abstract

Figures

Similar articles

Cited by

References

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources